Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis

Clinical Rheumatology

Volumn 22, Issue 6, 2003, Pages 371-375

  Nakamura, Tadashi ^a   Yamamura, Yuji ^a   Tomoda, Kunihiko ^a   Tsukano, Michishi ^a   Shono, Masahiro ^b   Baba, Satoshi ^c  

^a Kumamoto Center for Arthritis and Rheumatology   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclophosphamide combined with prednisolone; Rheumatoid arthritis; SAA1.3 allele; Secondary amyloidosis

Indexed keywords

ACTARIT; BUCILLAMINE; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; LOBENZARIT; MARKER; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; SERUM ALBUMIN; SERUM AMYLOID A; APOLIPOPROTEIN;

ADULT; AGED; ALLELE; AMYLOIDOSIS; ARTICLE; BIOPSY; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENOTYPE; HEMORRHAGIC CYSTITIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFECTION; JAPAN; MALE; PRIORITY JOURNAL; RANK SUM TEST; RHEUMATOID ARTHRITIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; GENETICS; HOSPITALIZATION; MIDDLE AGED; NONPARAMETRIC TEST; PROBABILITY; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AMYLOIDOSIS; APOLIPOPROTEINS; ARTHRITIS, RHEUMATOID; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; PREDNISOLONE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 2342511644     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-003-0763-9     Document Type: Article

References (23)

1. Baba S, Masago SA, Takahashi T et al. (1995) A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4:1083-1087
2. Baba S, Miyamoto S, Kawashima M et al. (1999) Serum amyloid A gene polymorphism and AA-amyloidosis. In: Kyle RA, Gertz MA, eds. Amyloid and amyloidosis. New York, Parthenon Publishing Group, :417-419
3. Cunnane G (2001) Amyloid precursors and amyloidosis in inflammatory arthritis. Cur Opin Rheumatol 13:67-73
4. Gillmore JO, Levitt LB, Jersey MA, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24-29
5. Joss N, McLaughlin K. Simpson K, Boulton-Jones JAM (2000) Presentation, survival and prognostic markers in AA amyloidosis. Q J Med 93:535-542
6. Ahlmen M, Ahlmen J, Svalander C, Bucht H (1987) Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 6:27-38
7. Berglund K, Thysell H, Keller C (1993) Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 20:2051-2057
8. Savolainen HA (1999) Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 26:898-903
9. Nakamura T, Baba S, Yamamura Y et al. (2000) Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis. Mod Rheumatol 10:160-164
10. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
11. Lansbury J (1977) The pooled index. J Rheumatol 4:445-446
12. Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662
13. Falck HM, Tornroth T, Skrifvars B, Wegelius O (1979) Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand 205:651-656
14. Berglund K, Keller C, Thysell H (1987) Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatoid arthritis. Ann Rheum Dis 46:757-762
15. Horslev-Petersen K, Beyer JM, Helin P (1983) Intermittent cyclophosphamide in refractory rheumatoid arthritis. Br Med J 287:711-712
16. Keysser G, Keysser C, Keysser M (1998) Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients. Z Rheumatol 57:101-107
17. Deschenes G, Prieur AM, Hayem F, Broyer A, Gubler MC (1990) Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 4:463-469
18. David J, Vouyiouka O, Ansell BM, Hall A, Woo P (1993) Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 2:85-90
19. Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70:246-256
20. Maezawa A, Hiromura K, Mitsuhashi H et al. (1994) Combined treatment with cyclophosphamide and prednisolone can induce remission of nephritic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 42:30-32
21. Gomez-Casanovas E, Sanmarti R, Sole M, Canate JD, Munoz-Gomez J (2001) The clinical significance of amyloid fat deposits in rheumatoid arthritis. A systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 44:66-72
22. Chevrel G, Jenvrin C, McGregor B, Miossec P (2001) Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology 40:821-825
23. Rochen C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440:111-122